Phase 2 Open Label Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
Maryanne Makredes Senna
Summary
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational study drug to learn whether the delgocitinib 20 mg/g cream works in treating a specific disease. "Investigational" means that the delgocitinib 20 mg/g cream is being studied.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any trial-related procedures. * Subjects must be willing to comply with all trial procedures and must be available for the duration of the trial. * Male or female subject aged 18 years of age or older at the time of consent. * Female subject of childbearing potential has had a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1. * Subject has clinically confirmed diagnosis of FFA based on investigator judgment. * Subject h…
Interventions
- DrugDelgocitinib
Everyone in this study receives the study drug (delgocitinib)
Location
- Lahey ClinicBurlington, Massachusetts